Role of GLP-1 Receptor Agonists beyond Glycemic Control: A Comprehensive Review

Dr Neeraj Manikath , claude.ai

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes mellitus since their introduction. While initially developed for glycemic control, emerging evidence demonstrates their profound pleiotropic effects extending far beyond glucose homeostasis. This review synthesizes current evidence on cardiovascular protection, renal benefits, weight management, hepatic effects, and emerging therapeutic applications of GLP-1 RAs. Understanding these multifaceted benefits is crucial for optimizing patient selection and maximizing therapeutic outcomes in contemporary clinical practice.

Keywords: GLP-1 receptor agonists, cardiovascular disease, chronic kidney disease, obesity, non-alcoholic fatty liver disease, pleiotropic effects

Introduction

The discovery of incretin hormones and subsequent development of GLP-1 receptor agonists represents a paradigm shift in metabolic medicine. GLP-1, a 30-amino acid peptide secreted by intestinal L-cells, exerts its effects through binding to GLP-1 receptors distributed throughout multiple organ systems including the pancreas, cardiovascular system, kidneys, brain, and gastrointestinal tract. This widespread receptor distribution provides the mechanistic foundation for the diverse clinical benefits observed with GLP-1 RAs.

Currently available GLP-1 RAs include short-acting formulations (exenatide, lixisenatide) and long-acting agents (dulaglutide, semaglutide, liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide). The evolution from twice-daily injections to once-weekly formulations and now oral preparations has substantially improved patient adherence and treatment satisfaction.

Pearl #1: The pleiotropic effects of GLP-1 RAs are dose-dependent. Higher doses used for obesity (semaglutide 2.4 mg weekly) demonstrate more pronounced cardiovascular and metabolic benefits compared to diabetes-approved doses, suggesting that maximizing the dose within safety parameters optimizes non-glycemic benefits.

Cardiovascular Benefits: Beyond Risk Factor Modification

Major Cardiovascular Outcome Trials

The cardiovascular benefits of GLP-1 RAs have been definitively established through landmark cardiovascular outcome trials (CVOTs). The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) demonstrated a 13% reduction in three-point major adverse cardiovascular events (MACE) with liraglutide versus placebo. Similarly, SUSTAIN-6 showed semaglutide reduced MACE by 26%, while REWIND demonstrated dulaglutide's 12% MACE reduction in a population with lower baseline cardiovascular risk.

Hack #1: When selecting a GLP-1 RA for patients with established atherosclerotic cardiovascular disease (ASCVD), prioritize agents with proven MACE reduction in CVOTs: liraglutide, semaglutide (injectable), dulaglutide, and efpeglenatide. Oral semaglutide (PIONEER-6) showed cardiovascular safety but not superiority—reserve injectable formulations for high-risk patients when possible.

Mechanisms of Cardiovascular Protection

The cardioprotective mechanisms of GLP-1 RAs extend beyond traditional risk factor improvement. Direct effects include:

Endothelial Function Enhancement: GLP-1 receptors on vascular endothelium mediate improved nitric oxide bioavailability and reduced oxidative stress. Studies demonstrate improved flow-mediated dilation within weeks of initiation, preceding significant weight loss.
Anti-inflammatory Effects: GLP-1 RAs reduce systemic inflammation markers including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. The anti-inflammatory action appears independent of weight reduction and contributes to plaque stabilization.
Direct Myocardial Effects: Experimental evidence suggests GLP-1 receptors in cardiomyocytes mediate improved calcium handling, reduced apoptosis, and enhanced contractility during ischemic stress. However, the clinical relevance remains debated as some studies question the density of cardiac GLP-1 receptors.
Blood Pressure Reduction: GLP-1 RAs consistently reduce systolic blood pressure by 2-6 mmHg through natriuretic effects and possibly central mechanisms, contributing to overall cardiovascular risk reduction.

Oyster #1: The cardiovascular benefits of GLP-1 RAs predominantly manifest as reduced atherosclerotic events (myocardial infarction, stroke) rather than heart failure outcomes. Patients with heart failure with reduced ejection fraction should not receive GLP-1 RAs expecting heart failure benefit—SGLT2 inhibitors remain superior for this indication. However, the SELECT trial with semaglutide 2.4 mg showed cardiovascular benefits in obesity without diabetes, expanding the treatment paradigm.

Stroke Prevention

Stroke reduction represents a particularly noteworthy benefit. SUSTAIN-6 demonstrated a remarkable 39% reduction in non-fatal stroke with semaglutide. The mechanisms likely involve improved endothelial function, blood pressure reduction, and potentially direct neuroprotective effects through GLP-1 receptors in cerebral vasculature.

Renal Protection: Nephrology's New Ally

Evidence from Clinical Trials

Renal benefits of GLP-1 RAs have emerged as a consistent finding across multiple trials. LEADER showed liraglutide reduced the composite renal outcome (new-onset macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or renal death) by 22%. SUSTAIN-6 demonstrated similar benefits with semaglutide, while FLOW (dulaglutide) specifically enrolled patients with chronic kidney disease and showed profound renal protection.

Pearl #2: GLP-1 RAs are particularly effective at preventing albuminuria progression. In patients with diabetic kidney disease and albuminuria, GLP-1 RAs can reduce albuminuria by 20-30% within 3-6 months, providing an early biomarker of therapeutic efficacy. Consider rechecking urine albumin-to-creatinine ratio at 3 months to confirm response.

Mechanisms of Renoprotection

The nephroprotective mechanisms are multifactorial:

Hemodynamic Effects: GLP-1 RAs induce natriuresis and may reduce intraglomerular pressure, similar to but distinct from RAAS inhibition. The combination with ACE inhibitors/ARBs provides additive renal protection.
Metabolic Improvements: Beyond glycemic control, improvements in blood pressure, weight, and systemic inflammation all contribute to reduced renal injury progression.
Direct Renal Effects: GLP-1 receptors in renal tubules mediate sodium excretion. Anti-inflammatory and anti-fibrotic effects in renal tissue have been demonstrated in experimental models.
Reduced Hyperfiltration: In early diabetic kidney disease, GLP-1 RAs may reduce pathologic hyperfiltration, potentially slowing long-term disease progression.

Hack #2: Don't discontinue GLP-1 RAs for mild-moderate renal impairment. Liraglutide, dulaglutide, and semaglutide require no dose adjustment down to eGFR 15 mL/min/1.73m². Only exenatide once-weekly should be avoided with eGFR <30. This makes GLP-1 RAs particularly valuable in advanced CKD where therapeutic options narrow.

Combination with SGLT2 Inhibitors

The complementary mechanisms of GLP-1 RAs and SGLT2 inhibitors create synergistic cardiorenal protection. Emerging evidence supports combination therapy in high-risk patients, though prospective trials specifically examining this combination are limited. The AMPLITUDE-O trial with efpeglenatide included patients on SGLT2 inhibitors, demonstrating additional cardiovascular benefit.

Weight Management: Neurohormonal Appetite Regulation

Mechanisms of Weight Loss

GLP-1 RAs induce weight loss through multiple mechanisms:

Central Appetite Suppression: GLP-1 receptors in the hypothalamus, particularly the arcuate nucleus and paraventricular nucleus, mediate reduced appetite and increased satiety. Functional MRI studies demonstrate reduced activation of reward centers in response to food cues.
Delayed Gastric Emptying: Short-acting GLP-1 RAs significantly delay gastric emptying, contributing to satiety. Long-acting agents demonstrate tachyphylaxis to this effect, with appetite suppression maintained through central mechanisms.
Improved Satiety Signaling: Enhanced sensitivity to endogenous satiety signals and reduced food reward perception contribute to sustainable caloric reduction.

Clinical Efficacy in Obesity

Higher-dose semaglutide (2.4 mg weekly) achieved mean weight loss of 15-17% in the STEP trial program, representing unprecedented pharmacologic weight reduction. Tirzepatide, the dual GIP/GLP-1 agonist, demonstrated even greater efficacy with up to 22.5% weight loss at the highest dose (15 mg) in the SURMOUNT trials.

Pearl #3: Weight loss with GLP-1 RAs follows a predictable trajectory. Maximum weight loss typically occurs at 60-68 weeks of treatment. Patients losing <5% body weight by 16 weeks are unlikely to achieve clinically meaningful weight loss—consider dose escalation or alternative therapies. Conversely, early responders (>5% loss by 12 weeks) predict excellent long-term outcomes.

Hack #3: To maximize weight loss efficacy while managing gastrointestinal side effects, employ gradual dose titration over 16-20 weeks rather than standard protocols. For semaglutide, consider increments of 0.5 mg every 4 weeks: 0.25 mg (4 weeks) → 0.5 mg (4 weeks) → 1.0 mg (4 weeks) → 1.7 mg (4 weeks) → 2.4 mg. This extended titration improves tolerability with minimal reduction in ultimate weight loss.

Body Composition and Metabolic Benefits

Importantly, GLP-1 RA-induced weight loss comprises approximately 25-40% lean mass loss, higher than desired but less than equivalent caloric restriction alone. Concurrent resistance exercise and adequate protein intake (1.2-1.6 g/kg/day) help preserve lean mass. The metabolic benefits of weight loss include improved insulin sensitivity, reduced visceral adiposity, decreased hepatic steatosis, and favorable lipid profile changes.

Hepatic Effects: A New Frontier in NAFLD/NASH

Emerging Evidence in Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), represent growing global health challenges. GLP-1 RAs demonstrate promising hepatoprotective effects through multiple mechanisms:

Reduction of Hepatic Steatosis: Studies using MRI proton density fat fraction demonstrate 30-40% relative reductions in hepatic fat content with GLP-1 RAs.
Improvement in Inflammatory Markers: Reductions in ALT, AST, and serum markers of hepatic inflammation suggest disease activity reduction.
Potential Anti-fibrotic Effects: While human data are limited, animal studies demonstrate reduced hepatic fibrosis with GLP-1 RA treatment. Ongoing trials (ESSENCE, SYNERGY-NASH) are evaluating fibrosis outcomes.

Oyster #2: Don't overlook hepatic benefits when prescribing GLP-1 RAs for diabetes or obesity. Approximately 70% of patients with type 2 diabetes have NAFLD, and 30-40% have significant fibrosis. A baseline non-invasive fibrosis assessment (FIB-4 score, vibration-controlled transient elastography) helps identify patients who will particularly benefit from hepatic effects.

Mechanisms Beyond Weight Loss

While weight loss substantially contributes to hepatic improvement, GLP-1 RAs exert direct hepatic effects:

Reduced De Novo Lipogenesis: Direct hepatic GLP-1 receptor activation (debated) or indirect effects through improved insulin sensitivity reduce lipogenesis.
Enhanced Lipid Oxidation: Increased hepatic fatty acid oxidation reduces lipid accumulation.
Anti-inflammatory Effects: Reduced hepatic inflammation through modulation of Kupffer cell activity and inflammatory cytokine production.

Pearl #4: For patients with NAFLD/NASH, consider GLP-1 RAs even without diabetes if BMI ≥30 kg/m² or BMI ≥27 kg/m² with metabolic complications. The SELECT trial established cardiovascular benefits in obesity without diabetes, and emerging data support metabolic benefits including NAFLD improvement in this population.

Neuroprotection and Cognitive Function

Potential in Neurodegenerative Diseases

GLP-1 receptors in the central nervous system, particularly the hippocampus and cortex, have generated interest in potential neuroprotective applications:

Alzheimer's Disease: Preclinical studies demonstrate reduced amyloid-beta accumulation, improved neuronal survival, and enhanced synaptic plasticity. Small human studies suggest liraglutide may slow cognitive decline in early Alzheimer's disease. Larger trials (EVOKE, EVOKE+) are ongoing.
Parkinson's Disease: Exenatide showed promising results in a phase 2 trial, with improved motor function persisting 12 months after treatment cessation. Mechanisms include reduced neuroinflammation and enhanced mitochondrial function.
Vascular Cognitive Impairment: Improved cerebrovascular function and reduced vascular inflammation may protect against vascular dementia.

Hack #4: While not yet standard practice, consider GLP-1 RAs favorably in diabetic patients with mild cognitive impairment or early dementia, particularly with vascular risk factors. The cognitive benefits, though preliminary, add to the comprehensive cardiometabolic advantages. Ensure family/caregiver involvement for medication administration and side effect monitoring.

Practical Clinical Considerations

Patient Selection Optimization

Strategic patient selection maximizes the multifaceted benefits of GLP-1 RAs:

Ideal Candidates:

Type 2 diabetes with established ASCVD or high cardiovascular risk
Diabetic kidney disease with albuminuria
Obesity (BMI ≥30 kg/m²) with or without diabetes
Type 2 diabetes with NAFLD/NASH
Patients requiring weight loss to achieve glycemic goals

Relative Contraindications:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2
History of severe gastroparesis
Active gallbladder disease (relative)

Managing Adverse Effects

Gastrointestinal Side Effects:

The most common adverse effects are nausea, vomiting, and diarrhea, typically occurring during dose escalation:

Prevention: Slow titration, taking medication with food (though not required), avoiding large or fatty meals
Management: Temporary dose reduction, anti-emetics (ondansetron, metoclopramide), ginger supplements
Duration: Usually resolves within 4-8 weeks; persistent symptoms warrant evaluation for other causes

Pearl #5: If nausea persists despite management strategies, try switching between GLP-1 RAs. Individual tolerability varies significantly—patients intolerant to one agent may tolerate another excellently. Consider switching from short-acting (more gastroparesis) to long-acting agents, or between long-acting agents.

Pancreatitis Risk:

While initially concerning, meta-analyses show no significant pancreatitis risk increase with GLP-1 RAs. However:

Obtain baseline lipase in patients with prior pancreatitis
Discontinue if acute pancreatitis develops
May rechallenge after resolution if benefits outweigh risks and alternative explanation for pancreatitis exists

Gallbladder Disease:

Rapid weight loss increases cholelithiasis risk. Counsel patients on warning signs; consider prophylactic ursodeoxycholic acid in very high-risk patients, though evidence is limited.

Hypoglycemia:

GLP-1 RAs alone rarely cause hypoglycemia due to glucose-dependent insulin secretion. However, combination with sulfonylureas or insulin requires dose reduction:

Reduce sulfonylurea dose by 50% when initiating GLP-1 RA
Reduce insulin (particularly prandial) by 20-30%
Monitor glucose closely during titration

Cost-Effectiveness Considerations

Despite high acquisition costs, GLP-1 RAs demonstrate cost-effectiveness in appropriate populations due to:

Reduced cardiovascular events and associated costs
Delayed or prevented renal replacement therapy
Reduced obesity-related complications
Improved quality of life

Hack #5: When insurance denies coverage, utilize manufacturer patient assistance programs, which often provide medication at reduced cost or free to eligible patients. Additionally, document multiple failed therapies, cardiovascular disease, or diabetic kidney disease to strengthen prior authorization appeals. Emphasize the cardiovascular and renal benefits beyond glycemic control in authorization requests.

Emerging Applications and Future Directions

Polycystic Ovary Syndrome (PCOS)

GLP-1 RAs show promise in PCOS management through weight loss, improved insulin sensitivity, and potential direct ovarian effects. Studies demonstrate improved menstrual regularity, reduced androgens, and enhanced fertility outcomes.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The evolving nomenclature from NAFLD to MASLD reflects improved understanding of metabolic liver disease. Ongoing phase 3 trials evaluating GLP-1 RAs for MASLD/MASH (metabolic dysfunction-associated steatohepatitis) will likely expand indications.

Heart Failure with Preserved Ejection Fraction (HFpEF)

While data remain limited compared to SGLT2 inhibitors, weight loss and metabolic improvements with GLP-1 RAs may benefit HFpEF patients, particularly those with obesity. The STEP-HFpEF trial showed semaglutide improved symptoms and physical limitations in obese HFpEF patients.

Addiction Medicine

Emerging evidence suggests GLP-1 RAs may reduce alcohol consumption and other addictive behaviors through effects on reward pathways. While preliminary, this represents an exciting frontier.

Oyster #3: The enthusiasm around GLP-1 RAs must be tempered with recognition of their limitations. They do not replace lifestyle modification, require long-term (likely lifelong) administration, have significant gastrointestinal side effects in many patients, and weight regain commonly occurs upon discontinuation. Set realistic expectations with patients regarding commitment required for sustained benefits.

Comparative Effectiveness: Choosing Among GLP-1 RAs

Efficacy Differences

While head-to-head trials are limited, network meta-analyses suggest efficacy hierarchy:

Glycemic Control: Tirzepatide > Semaglutide 2.0 mg > Dulaglutide 4.5 mg > Liraglutide 1.8 mg

Weight Loss: Tirzepatide 15 mg > Semaglutide 2.4 mg > Semaglutide 1.0 mg > Dulaglutide 4.5 mg > Liraglutide 1.8 mg

Cardiovascular Outcomes: All agents with CVOT data show benefit; indirect comparisons suggest semaglutide may have slight advantage, but differences are not definitively established.

Practical Selection Criteria

Once-Weekly Convenience: Semaglutide, dulaglutide, tirzepatide (emerging oral formulations may change this landscape)

Cardiovascular Disease Priority: Semaglutide (injectable), liraglutide, dulaglutide

Maximum Weight Loss: Tirzepatide 15 mg, semaglutide 2.4 mg

Renal Impairment: Liraglutide, dulaglutide, semaglutide (no adjustment needed)

Cost Sensitivity: Consider patient assistance programs; sometimes older agents (liraglutide) have better insurance coverage

Pearl #6: The "best" GLP-1 RA is the one the patient will actually use. Patient preference regarding injection frequency, device usability, and side effect profile significantly impacts adherence. Involve patients in decision-making, demonstrate injection techniques, and ensure they're comfortable with their chosen agent.

Monitoring and Long-term Management

Baseline Assessment

Prior to initiation:

Comprehensive metabolic panel, lipid profile, HbA1c
Urine albumin-to-creatinine ratio
Calculated eGFR
Liver function tests (if NAFLD suspected)
Thyroid function (document baseline)
Retinopathy screening (theoretical concern for rapid glycemic improvement)

Follow-up Monitoring

First 3 Months:

Assess tolerance, gastrointestinal side effects
Review glucose logs if on insulin or sulfonylureas
Weight at each visit during titration
HbA1c at 3 months

Long-term (every 3-6 months):

HbA1c every 3-6 months
Annual comprehensive metabolic panel, lipid profile
Annual urine albumin-to-creatinine ratio
Weight, blood pressure at each visit
Annual retinopathy screening
Periodic assessment of continued need and benefit

Hack #6: Create a simple checklist template in your electronic medical record for GLP-1 RA monitoring. Include prompts for dose titration schedules, side effect screening questions, and appropriate lab ordering. This systematizes care and ensures comprehensive management without overwhelming your workflow.

Special Populations

Elderly Patients

GLP-1 RAs are generally safe in elderly patients, but considerations include:

Higher risk of dehydration from gastrointestinal side effects
Greater concern for sarcopenia with weight loss—emphasize resistance exercise and protein intake
Potential for polypharmacy interactions
May need assistance with injections

Benefits often outweigh risks given high cardiovascular risk in this population.

Chronic Kidney Disease

GLP-1 RAs are increasingly important in CKD management:

Proven renal protection across CKD stages
No dose adjustment needed for most agents
Complement RAAS inhibition and SGLT2 inhibitors
Consider even in advanced CKD (stages 4-5) given safety profile

Pregnancy and Lactation

GLP-1 RAs are not recommended during pregnancy or lactation due to insufficient safety data. Discontinue prior to planned conception; if pregnancy occurs while on treatment, discontinue immediately and transition to insulin if needed.

Conclusion

GLP-1 receptor agonists represent one of the most significant therapeutic advances in metabolic medicine of the past two decades. Their profound pleiotropic effects—cardiovascular protection, renal preservation, substantial weight loss, hepatic benefits, and potential neuroprotection—extend far beyond their original indication for glycemic control. As clinicians, we must evolve beyond viewing GLP-1 RAs as mere glucose-lowering agents and instead recognize them as comprehensive cardiometabolic therapeutics.

The challenge lies not in the evidence supporting their use, which is robust and growing, but in ensuring appropriate patient access, managing expectations and side effects, and integrating these agents thoughtfully into individualized treatment plans. As the therapeutic landscape continues to evolve with new formulations, combination therapies, and expanded indications, GLP-1 RAs will undoubtedly remain central to our therapeutic armamentarium for years to come.

The key to optimal utilization lies in understanding not just what these drugs do, but how to strategically deploy them to maximize benefit while minimizing harm—an art as much as a science, requiring the clinical wisdom that comes from experience and continued learning.

Key Clinical Pearls Summary

Higher doses maximize non-glycemic benefits; dose-dependent effects
Albuminuria reduction by 20-30% within 3-6 months predicts renal benefit
Early weight loss (<5% by 12-16 weeks) predicts long-term success
Consider for NAFLD in diabetes patients regardless of transaminases
Switch between agents if intolerance occurs; individual variation is substantial
Patient preference and adherence trump theoretical "best" agent selection

Clinical Hacks Summary

Prioritize injectable semaglutide, liraglutide, or dulaglutide for established ASCVD
No dose adjustment needed for renal impairment (except exenatide once-weekly)
Extended titration schedule (4-week increments) improves GI tolerability
Consider GLP-1 RAs in diabetic patients with mild cognitive impairment
Leverage manufacturer assistance programs and document comprehensively for authorizations
Create EHR checklist templates for systematic monitoring and management

References

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl Med. 2016;375(19):1834-1844.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.
Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocr Pract. 2022;28(10):923-1049.
Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084.
Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041-2051.

Conflicts of Interest:none

Funding: None